Forensics gone wrong: When DNA snares the innocent
By Douglas Starr,
Science/AAAS
| 03. 07. 2016
On a Tuesday morning in Boise, biologist Greg Hampikian is on speakerphone with Christopher Tapp, an inmate at the Idaho State Correctional Institution. Tapp is in prison for a murder he swears he did not commit. Many others think he’s innocent as well—lawyers, journalists, an organization of former judges; even the victim’s mother. No one has fought for him longer than Hampikian, a researcher at Boise State University (BSU). “How’re you doing, Chris?” Hampikian begins. “I’m having a good time at summer camp,” Tapp says gamely. “Although you know me … I’m in the hole again”—solitary. “There was a mutual misunderstanding between me and someone else.” He mentions that he and his wife are getting divorced.
“I’m really sorry Chris, that’s a lot to deal with,” Hampikian says. “You know my offer still stands. I’ll pay tuition for any courses you want to take.” A pause. “You know we got a decision from the court to move forward with a new DNA test. But the court is only allowing us a limited amount and we have to decide which test is...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...